Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib in Relapsed/Refractory iNHL
NCT03711578Phase 2Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tenalisib in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Rhizen Pharmaceuticals AG. Primary endpoints: Objective Response Rate at 7 months, Complete Response Rate at 7 months and 2 more. Started Nov 2018; status: completed.
02
Drugs
tenalisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT03711578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711578.